Ficlatuzumab

立即咨询

Ficlatuzumab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1174900-84-5

Ficlatuzumab 是一种靶向人肝细胞生长因子 (HGF) 的单克隆抗体 (McAb)。Ficlatuzumab 能够阻断HGF/c-Met信号通路的激活，抑制c-Met受体介导的癌细胞增殖、迁移和侵袭。

生物活性

Ficlatuzumab is a monoclonal antibody (McAb) targetinghuman hepatocyte growth factor(HGF). Ficlatuzumab blocks the activation of theHGF/c-Metsignaling pathway, and inhibitsc-Metreceptor-mediatedcancercell proliferation, migration, and invasion^[1].

IC₅₀& Target

HGF/c-Met^[1]

体外研究
(In Vitro)

Ficlatuzumab (20 μg/mL; 24 h) effectively decreases tumor-associated fibroblast (TAF)-conditioned media-facilitated HNSCC migration and invasion^[1].
Ficlatuzumab (20 μg/mL; 24 h) effectively mitigates TAF-facilitated epithelial-tomesenchymal transition (EMT), Vimentin expression in HNSCC cells^[1].
Ficlatuzumab (20 μg/mL; 72 h) reduces proliferation induced by TAF-secreted hepatocyte growth factor (HGF) in HNSCC cells^[1].
Ficlatuzumab (20 μg/mL; 16 h) reduces the phosphorylation of c-Met and p44/42 MAPK in HNSCC cells compared with cells treated with recombinant HGF alone^[1].

Clinical Trial

性状

Liquid

CAS 号

1174900-84-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.